# A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis

> **NCT05235269** · PHASE2 · COMPLETED · sponsor: **Attralus, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** 124I-AT-01

## Key facts

- **NCT ID:** NCT05235269
- **Lead sponsor:** Attralus, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2023-02-06
- **Final completion:** 2023-02-24
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05235269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05235269, "A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05235269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*